A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Learn more about IN8BIO, Inc.’s (INAB) stock grades for Growth, Estimate Revisions and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Jack Gilleland
| Share Statistics | INAB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $10.2 | $252.6 | 7% |
|
| Shares Out (Mil) | 19.5 | 52.3 | 30% |
|
| Institutional Ownership | 88.9% | 92.1% | 57% |
|
| Float (Mil) | 7.2 | 40.2 | 16% |
|
| Beta | 0.19 | 0.95 | 12% |
|
| Avg Daily Volume (000s) | 49 | 455 | 28% |
|
| Price Change (52-week) |
(51.9%) | 52.9% | 15% |
|
| Growth | INAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (17.7%) | (9.9%) | 22% |
|
| EPS (5yr) | 45.3% | 16.0% | 91 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (52.6%) | (15.6%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 4 | 4 | |
| Current EPS | ($0.373) | ($1.243) | ($1.060) | |
| Month Ago EPS | ($0.373) | ($1.243) | ($1.060) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.730) | ($2.497) | ($1.508) | |
| Year/Year Chg | 42.9% | (72.0%) | (83.6%) | |
| Financials | INAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($19) | ($43) | 24% |
|
| EPS (TTM) | ($2.208) | ($1.600) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($15) | ($31) | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $5 | 18% |
|
| Enterprise Value (Q1) (Mil) | ($6) | $180 | 2% |
|
| Valuation | INAB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.45 | 2.56 | 8% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | INAB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (82.3%) | (49.8%) | 7% |
|
| ROE | (103.6%) | (55.5%) | 9% |
|
| Liabilities to Assets | 13.3% | 30.3% | 8% |
|
| F-Score | 4 | 3 | 34% |
|
IN8bio, Inc. did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
